Genetic ablation of NUDT21 impairs CRC cell proliferation and triggers CD8<sup>+</sup> T cell anti-tumor response through disrupting cholesterol biosynthesis, leading to delayed tumor progression in syngeneic mouse models. This evidence concerns the gene CD8A and colorectal carcinoma.